Article
Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
Anticancer research - 1 Sept 2014
Hsu Chih-Chieh, Wu Chiao-En, Chen Jen-Shi, Tseng Jeng-Hwei, Chiang Kun-Chun, Liu Yu-Yin, Tsai Chun-Yi, Cheng Chi-Tung, Chen Tsung-Wen, Jan Yi-Yin, Yeh Ta-Sen, Chen Yen-Yang, Yeh Chun-Nan
Abstract excerpt
AIM: Imatinib mesylate (IM) is effective in metastatic gastrointestinal stromal tumor (GIST) patients; however, disease progression eventually occurs due to IM resistance or intolerance. Treatment options include IM escalation or a direct shift to sunitinib, but comparison of these strategies is required. PATIENTS AND METHODS: This study included 91 out of 214 metastatic GIST patients treated with IM, who...
Topics
Join the communities discussing this publication.